The role of antimicrobials in the treatment of sepsis and critical illness-related bacterial infections: Examination of the evidence

Journal of Veterinary Emergency and Critical Care

Volumn 25, Issue 1, 2015, Pages 55-62

  Keir, Iain ^a   Dickinson, Amy E ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Pittsburgh Veterinary Specialty and Emergency Center   (United States)

Author keywords

Bacterial resistance; Biomarkers; Timing of therapy

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS;

ANTIINFECTIVE AGENT;

ANIMAL; BACTEREMIA; CAT; CAT DISEASES; DOG; DOG DISEASES; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; HUMAN; INTENSIVE CARE; PRACTICE GUIDELINE; SHOCK, SEPTIC; VETERINARY; VETERINARY MEDICINE;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTEREMIA; CAT DISEASES; CATS; CRITICAL CARE; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SHOCK, SEPTIC; VETERINARY MEDICINE;

EID: 84922768432     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/vec.12272     Document Type: Review

References (45)

1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41(2):580-637.
2. Boller M, Fletcher DJ. RECOVER evidence and knowledge gap analysis on veterinary CPR. Part 1: Evidence analysis and consensus process: collaborative path toward small animal CPR guidelines. J Vet Emerg Crit Care 2012; 22(Suppl 1):S4-12.
3. Bleck TP. Alternatives to evidence based medicine. Different rating scale could be used. BMJ 2000; 321(7255):239.
4. Goutal CM, Keir I, Kenney S, Rush JE, Freeman LM. Evaluation of acute congestive heart failure in dogs and cats: 145 cases (2007-2008). J Vet Emerg Crit Care 2010; 20(3):330-337.
5. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110(9):3507-3512.
6. Kale S, Yende S, Kong L, et al. The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumonia. PLoS One 2010; 5(11):e13852.
7. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596.
8. Cullen M, Fogg T, Delaney A. Timing of appropriate antibiotics in patients with septic shock: a retrospective cohort study. Emerg Med Australas 2013; 25(4):308-315.
9. Bruns AHW, Oosterheert JJ, Hustinx WNM, et al. Time for first antibiotic dose is not predictive for the early clinical failure of moderate-severe community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28(8):913.
10. Kanji Z, Dumaresque C. Time to effective antibiotic administration in adult patients with septic shock: a descriptive analysis. Intensive Crit Care Nurs 2012; 28(5):288-293.
11. Siddiqui S, Razzak J. Early versus late pre-intensive care unit admission broad spectrum antibiotics for severe sepsis in adults. Cochrane Database Syst Rev 2010; (10):CD007081.
12. Corona A, Bertolini G, Lipman J, et al. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010; 65(6):1276-1285.
13. Scarsi KK, Feinglass JM, Scheetz MH, et al. Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. Antimicrob Agents Chemother 2006; 50(10):3355-3360.
14. McGregor JC, Rich SE, Harris AD, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007; 45(3):329-337.
15. Quattromani E, Powell ES, Khare RK, et al. Hospital-reported data on the pneumonia quality measure "Time to First Antibiotic Dose" are not associated with inpatient mortality: results of a nationwide cross-sectional analysis. Acad Emerg Med 2011; 18(5):496-503.
16. Kumar A. An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy. Virulence 2014; 5(1):80-97.
17. Kumar A, Haery C, Paladugu B, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006; 193(2):251-258.
18. Lala HM, Mills GD, Barratt K, et al. Meningococcal disease deaths and the frequency of antibiotic administration delays. J Infect 2007; 54(6):551-557.
19. Øvstebø R, Brandtzaeg P, Brusletto B, et al. Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 2004; 42(7):2980-2987.
20. Paul M, Shani V, Muchtar E, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54(11):4851-4863.
21. Ehrlich P. Address in pathology, on chemiotherapy: delivered before the Seventeenth International Congress of Medicine. Br Med J 1913; 2(2746):353-359.
22. Peng Z-Y, Wang H-Z, Srisawat N, et al. Bactericidal antibiotics temporarily increase inflammation and worsen acute kidney injury in experimental sepsis. Crit Care Med 2012; 40(2):538-543.
23. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care 2011; 15(6):R267.
24. Dimopoulos G, Poulakou G, Pneumatikos IA, et al. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013; 144(6):1759-1767.
25. Havey TC, Fowler RA, Pinto R, et al. Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study. Can J Infect Dis Med Microbiol 2013; 24(3):129-37.
26. Wise MP, Morgan MPG, Saayman AG. Duration of antibiotic therapy in bacteraemia. Crit Care 2012; 16(1):403.
27. Murray C, Shaw A, Lloyd M, et al. A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. J Antimicrob Chemother 2014; 69(2):515-518.
28. Eliakim-Raz N, Yahav D, Paul M, et al. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013; 68(10):2183-2191.
29. Scawn N, Saul D, Pathak D, et al. A pilot randomised controlled trial in intensive care patients comparing 7 days' treatment with empirical antibiotics with 2 days' treatment for hospital-acquired infection of unknown origin. Health Technol Assess 2012; 16(36):i-xiii, 1-70.
30. Quenot J-P, Luyt C-E, Roche N, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care 2013; 3(1):21-38.
31. Oliveira CF, Botoni FA, Oliveira CRA, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med 2013; 41(10):2336-2343.
32. Bouadma L, Luyt C-E, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375(9713):463-474.
33. Hochreiter M, Köhler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 2009; 13(3):R83.
34. Hemels MAC, van den Hoogen A, Verboon-Maciolek MA, et al. Shortening the antibiotic course for the treatment of neonatal coagulase-negative staphylococcal sepsis: fine with three days? Neonatology 2012; 101(2):101-105.
35. Abelson AL, Buckley GJ, Rozanski EA. Positive impact of an emergency department protocol on time to antimicrobial administration in dogs with septic peritonitis. J Vet Emerg Crit Care 2013; 23(5):551-556.
36. Proulx A, Hume DZ, Drobatz KJ, et al. In vitro bacterial isolate susceptibility to empirically selected antimicrobials in 111 dogs with bacterial pneumonia. J Vet Emerg Crit Care 2014; 24(2):194-200.
37. Dickinson AE, Summers J, Wignal J, et al. Impact of appropriate empirical antimicrobial therapy on outcome of dogs with septic peritonitis. J Vet Emerg Crit Care 2015; 25(1):152-159.
38. Kompare B, Litster AL, Leutenegger CM, et al. Randomized masked controlled clinical trial to compare 7-day and 14-day course length of doxycycline in the treatment of Mycoplasma felis infection in shelter cats. Comp Immunol Microbiol Infect Dis 2013; 36(2):129-135.
39. Floras ANK, Holowaychuk MK, Hodgins DC, et al. Investigation of a commercial ELISA for the detection of canine procalcitonin. J Vet Intern Med 2014; 28(2):599-602.
40. Fransson BA, Bergström A, Wardrop KJ, et al. Assessment of three automated assays for C-reactive protein determination in dogs. Am J Vet Res 2007; 68(12):1281-1286.
41. Wittebole X, De Roock S, Opal SM. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014; 5(1):226-235.
42. Uchiyama J, Takemura I, Hayashi I, et al. Characterization of lytic enzyme open reading frame 9 (ORF9) derived from Enterococcus faecalis bacteriophage phiEF24C. Appl Environ Microbiol 2011; 77(2):580-585.
43. Vinodkumar CS, Neelagund YF, Kalsurmath S. Bacteriophage in the treatment of experimental septicemic mice from a clinical isolate of multidrug resistant Klebsiella pneumoniae. J Commun Dis 2005; 37(1):18-29.
44. Vinodkumar CS, Kalsurmath S, Neelagund YF. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol 51(3):360-366.
45. Pouillot F, Chomton M, Blois H, et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother 2012; 56(7):3568-3575.